PIK3CB and colorectal cancer: Another compelling study demonstrates the reversal of resistance to pan-PI3K, PI3Kα-selective, dual PI3K/mTOR, and AKT inhibitors in colorectal cancer patient-derived organoids and PDX models using a Wnt/tankyrase inhibitor, NVP-TNKS656 [54].